Dr Kirsty McDowell

  • Honorary Clinical Fellow (School of Cardiovascular & Metabolic Health)

email: Kirsty.McDowell.2@glasgow.ac.uk

Queen Elizabeth University Hospital, G51 4TF

Import to contacts

Publications

List by: Type | Date

Jump to: 2025 | 2024 | 2023 | 2022
Number of items: 10.

2025

Docherty, K. F. et al. (2025) Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin : an exploratory analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.12.012) (PMID:40088234) (In Press)

2024

McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

McDowell, Kirsty, Adamson, Carly, Jackson, Collette, Campbell, Ross ORCID logoORCID: https://orcid.org/0000-0002-0050-2129, Welsh, Paul ORCID logoORCID: https://orcid.org/0000-0002-7970-3643, Petrie, Mark C. ORCID logoORCID: https://orcid.org/0000-0002-6333-9496, McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975, Jhund, Pardeep ORCID logoORCID: https://orcid.org/0000-0003-4306-5317 and Herring, Neil (2024) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, 26(1), pp. 107-116. (doi: 10.1002/ejhf.3085) (PMID:37937329)

2023

Glen, Claire, Adam, Sarah, McDowell, Kirsty, Waterston, Ashita, Tan, Yun Yi, Petrie, Mark C. ORCID logoORCID: https://orcid.org/0000-0002-6333-9496, Coats, Caroline J. ORCID logoORCID: https://orcid.org/0000-0002-3208-470X and Lang, Ninian N. ORCID logoORCID: https://orcid.org/0000-0001-8441-6887 (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)

Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)

2022

McDowell, Kirsty, Jhund, Pardeep S. ORCID logoORCID: https://orcid.org/0000-0003-4306-5317 and McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975 (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)

McDowell, Kirsty and Docherty, Kieran F. ORCID logoORCID: https://orcid.org/0000-0002-5446-9969 (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

This list was generated on Sun Jun 15 18:13:30 2025 BST.
Jump to: Articles
Number of items: 10.

Articles

Docherty, K. F. et al. (2025) Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin : an exploratory analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.12.012) (PMID:40088234) (In Press)

McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

McDowell, Kirsty, Adamson, Carly, Jackson, Collette, Campbell, Ross ORCID logoORCID: https://orcid.org/0000-0002-0050-2129, Welsh, Paul ORCID logoORCID: https://orcid.org/0000-0002-7970-3643, Petrie, Mark C. ORCID logoORCID: https://orcid.org/0000-0002-6333-9496, McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975, Jhund, Pardeep ORCID logoORCID: https://orcid.org/0000-0003-4306-5317 and Herring, Neil (2024) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, 26(1), pp. 107-116. (doi: 10.1002/ejhf.3085) (PMID:37937329)

Glen, Claire, Adam, Sarah, McDowell, Kirsty, Waterston, Ashita, Tan, Yun Yi, Petrie, Mark C. ORCID logoORCID: https://orcid.org/0000-0002-6333-9496, Coats, Caroline J. ORCID logoORCID: https://orcid.org/0000-0002-3208-470X and Lang, Ninian N. ORCID logoORCID: https://orcid.org/0000-0001-8441-6887 (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)

Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)

McDowell, Kirsty, Jhund, Pardeep S. ORCID logoORCID: https://orcid.org/0000-0003-4306-5317 and McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975 (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)

McDowell, Kirsty and Docherty, Kieran F. ORCID logoORCID: https://orcid.org/0000-0002-5446-9969 (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

This list was generated on Sun Jun 15 18:13:30 2025 BST.